DIO2 is largely responsible for the local conversion of T4 to T3 in extrathyroidal target tissues ( Reference Kohrle, Jakob and Contempre 69 )
Primary antibodies included anti--Catenin, anti-GSK3, anti-phospho-GSK3, anti-GAPDH, and anti--tubulin (Boster Biological Technology, Pleasanton, CA, United States), anti-Bcl2, anti-Bax, and anti-Cyclin D1 (Abcam plc, Cambridge, United Kingdom), anti-Akt and anti-phospho-Akt (Cell Signaling Technology, Danvers, MA, United Ststes), anti-Wnt10b, anti-CDK2, anti-CDK4, and anti-P21 (ABclonal, Wuhan, China), and anti-ki67 (Proteintech, Wuhan, China)
Research (primarily in animal models) has shown potential effects such as: Supporting soft tissue repair (muscle, tendon, ligament) Promoting angiogenesis (formation of new blood vessels) Supporting gastrointestinal integrity and mucosal protection Modulating inflammatory responses While these findings are promising, clinical research in humans remains limited, and results should be interpreted with caution
However, long-term human data is limited
